Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 11/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.51 |
| ▸ | CDK2 | P24941 | 11/20 | 0.51 |
| ▸ | CDK4 | P11802 | 5/20 | 0.47 |
| ▸ | CCND1 | P24385 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956841 | 0.83 | MAPT (0.59) | ALDH1A1HPGDKDM4EGAAHSD17B10 | |
| SCHEMBL4958351 | 0.79 | MAPT (0.34) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL4958613 | 0.79 | MAPT (0.55) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL4958290 | 0.79 | EGFR (0.34) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL20334273 | 0.79 | MAOA (0.90) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL29986841 | 0.77 | MAOA (0.87) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL4956547 | 0.75 | EGFR (0.37) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL4954966 | 0.75 | EGFR (0.34) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL4954958 | 0.75 | MAPT (0.34) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL4956778 | 0.75 | EGFR (0.34) | MAOAALDH1A1HPGDKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968602-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2018-05-15 | — | — | US | claimed |
| US-20140030317-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | Occhiuti & Rohlicek LLP | 2014-01-30 | — | — | US | claimed |
| US-7326690-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2008-02-05 | — | — | US | claimed |
| US-20070142303-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2007-06-21 | — | — | US | claimed |
| US-12246068-B2 | Enzymatically activatable peptide-redox modulator conjugates and use thereof | BRANDEIS UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| WO-2018129171-A1 | ENZYMATICALLY ACTIVATABLE PEPTIDE-REDOX MODULATOR CONJUGATES AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2018-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246068-B2 | Enzymatically activatable peptide-redox modulator conjugates and use thereof | GPX1, GPX4, ENPEP | MAOA 1166/4885ALDH1A1 777/4885HPGD 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.